Dr. Reddy’s Laboratories (NYSE:RDY) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Dr. Reddy’s Laboratories (NYSE:RDY) released its quarterly earnings results on Thursday. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01, Zacks reports. Dr. Reddy’s Laboratories had a return on equity of 18.53% and a net margin of 17.81%.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $14.16 on Friday. Dr. Reddy’s Laboratories has a 52 week low of $13.61 and a 52 week high of $16.89. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The stock has a market cap of $11.82 billion, a price-to-earnings ratio of 22.61 and a beta of 0.51. The business has a 50-day simple moving average of $14.87 and a two-hundred day simple moving average of $15.53.

Analyst Upgrades and Downgrades

RDY has been the subject of a number of recent research reports. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Barclays cut their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Finally, Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.